

Claims

1. A purified and isolated non-naturally occurring nucleic acid ligand to a fibrillar protein target, wherein said ligand is an RNA ligand selected from the group comprising:
 - 5 (i) the nucleic acid depicted in any one of SEQ ID NOS: 1, 61, 38 or 74;
 - (ii) having the corresponding DNA or RNA sequences of any one of SEQ ID NOS: 1, 61, 38 or 74 or the corresponding fully complementary sequences thereof or their L-ribose derivatives;
 - 10 (iii) derivatives of the sequence depicted in any one of SEQ ID NOS: 1, 61, 38 or 74 having at least about 60%, 70%, 80% or 90% sequence identity to any one of the nucleotide sequences, and which have a binding affinity to a fibrillar protein.
2. The nucleic acid ligand according to claim 1 which is substantially homologous to and has substantially the same ability to bind said fibrillar protein target as a ligand selected from the group comprising the nucleic acids depicted in any one of SEQ ID NOS: 1, 61, 38 or 74.
3. The nucleic acid ligand according to either preceding claim which has substantially the same structure and the same ability to bind said fibrillar protein target as a ligand selected from the group comprising the nucleic acids depicted in any one of SEQ ID NOS: 1, 61, 38 or 74..
4. The nucleic acid according to any preceding claim wherein the fibrillar protein target comprises either L- or D-amino acid molecules.
5. The nucleic acid according to any preceding wherein SEQ ID NO: 1 has a preferential binding affinity to a D-amino acid A β 1-40 monomeric target.
6. The nucleic acid according to any preceding claim further including any one or more of the following features:
 - 30 (i) a fluorescent label;

1. MAR. 2005 13:20

HARRISON GODDARD FOO

NO. 299

P. 14

- (ii) an imaging label or;
- (iii) a flanking region.

7. The nucleic acid according to claim 6 wherein the flanking region comprises
5 any one or more nucleic acid sequences selected from the group comprising SEQ ID
NOS: 56, 57, 106 and 107.

8. A vector comprising at least one or more nucleic acid as defined in any preceding claim.

9. A host cell including at least one or more nucleic acid as defined in any of claims 1 to 7 or the vector of claim 8.

10. A pharmaceutical comprising at least one nucleic acid as defined in any one
15 of claims 1 to 7 or the vector of claim 8.

11. A pharmaceutical according to claim 10 comprising a number of nucleic acid ligands each with binding affinities for the same or different forms of a fibrillar protein.

12. A pharmaceutical according to either claim 10 or 11 further including a suitable excipient, diluent or carrier.

13. Use of a nucleic acid according to any one of claims 1 to 7 for the
25 manufacture of a medicament for treating amyloid diseases.

14. Use according to claim 13 for the treatment of Alzheimer's and DRA disease conditions.

30 15. A method of treating a patient suffering from Alzheimer's disease or a disease associated with amyloid formation comprising administering a therapeutically

1. MAR. 2005 13:20

HARRISON GODDARD FOO

NO. 299 P. 15

effective amount of a nucleic acid ligand according to any one of claims 1 to 7, or the vector of claim 8 or a pharmaceutical according to claims 10 to 12.

16. A method according to claim 15 wherein the therapeutically effective amount
5 of a nucleic acid ligand or vector or pharmaceutical is administered by an intra-
venous, intra-muscular, intra-peritoneal route and optionally is administered on more
than one occasion.

17. Use of the nucleic acid according to any one of claims 1 to 7 or the vector of
10 claim 8 as a diagnostic agent for detecting the presence and/or progression of an
amyloid disease.

18. A method of monitoring the presence and/or progression of an amyloid disease comprising administering to a patient at least one nucleic acid according to any one of claims 1 to 7 or the vector of claim 8 or a pharmaceutical according to any one of claims 10 to 12 and imaging the presence of binding of said nucleic acid ligand to an amyloid fibril and optionally repeating the process at a later date to assess presence or progression of a disease state.

20 19. A purified and isolated non-naturally occurring nucleic acid ligand to a fibrillar protein target, wherein said ligand is an RNA ligand selected from the group comprising:

(iv) the nucleic acid depicted in any one of SEQ ID NOS: 2-37, 39-55, 58-60, 62-73 or 75-105;

25 (v) having the corresponding DNA or RNA sequences of any one of SEQ ID NOS: : 2-37, 39-55, 58-60, 62-73 or 75-105 or the corresponding fully complementary sequences thereof or their L-ribose derivatives;

(vi) derivatives of the sequence depicted in any one of SEQ ID NOS: : 2-37, 39-55, 58-60, 62-73 or 75-105 having at least about 60%, 70%,

30 80% or 90% sequence identity to any one of the nucleotide sequences, and which have a binding affinity to a fibrillar protein.

1. MAR. 2005 13:20

HARRISON GODDARD FOO

NO. 299 P. 16

20. The nucleic acid according to claim 19 wherein the fibrillar protein target is selected from the group comprising monomeric $\beta 2m$ or A β 1-40 or A β 1-42, protofibrillar $\beta 2m$ or A β 1-40 or A β 1-42, mature fibrillar $\beta 2m$ or A β 1-40 or A β 1-42.

5 21. The nucleic acid according to any preceding wherein the nucleic acid of any one of SEQ ID NOS: 2 to 16 have a preferential binding affinity to a D-amino acid A β 1-40 monomeric target.

10 22. The nucleic acid according to any one of claims 19 to 21 wherein the nucleic acid of any one of SEQ ID NOS: 17 to 36 have a preferential binding affinity to a D-amino acid A β 1-40 pre-fibrillar target.

15 23. The nucleic acid according to any one of claims 19 to 21 wherein the nucleic acid of any one of SEQ ID NOS: 37, 39 to 55 have a preferential binding affinity to a D-amino acid A β 1-40 protofibril target.

20 24. The nucleic acid according to any one of claims 19 to 21 wherein the nucleic acid of any one SEQ ID NOS: 58 to 60 or 62 to 71 have a preferential binding affinity to a native $\beta 2$ -microglobulin protein target.

25 25. The nucleic acid according to any one of claims 19 to 21 wherein the nucleic acid of any one of SEQ ID NOS: 72, 73 or 75 to 90 have a preferential binding affinity to a $\beta 2$ -microglobulin immature fibril protein target.

26 26. The nucleic acid according to any one of claims 19 to 21 wherein the nucleic acid of any one of SEQ ID NOS: 91 to 105 have a preferential binding affinity to a $\beta 2$ -microglobulin mature fibrillar protein target.

30 27. The nucleic acid according to any one of claims 19 to 26 further including any one or more of the features of claims 2 to 18.

28. Use of a binding motif comprising a peptide sequence derived from human β 2m that retains the ability of the whole protein to form amyloid fibrils, as a target for selecting a nucleic acid ligand.

5 29. Use of a peptide sequence comprising any one of SEQ ID NO: 111, 112 or 113 or derivatives or variants thereof that retain the ability of the whole protein to form amyloid fibrils, as a target for selecting a nucleic acid ligand.

10 30. A purified and isolated non-naturally occurring nucleic acid ligand to a fibrillar protein target, wherein the target comprises a binding motif as defined in either claim 28 or 29.

15 31. A purified and isolated non-naturally occurring nucleic acid ligand to a fibril cross β -core protein target.

20

25

30 P100255wo.claims filed 01-03-05